| Drug NDC: | 62185-0052 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | D1 Organ Support |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Carduus Marianus, Chelidonium Majus, Lycopodium Clavatum, Taraxacum Officinale, Avena Sativa, Cynara Scolymus, Methylcobalamin, Menadione, Alpha-lipoicum Acidum, Cinchona Officinalis, Hepar Suis, Veratrum Album, Colon (suis), Duodenum (suis), Gallbladder (suis), Intestine (suis), Lymph Node (suis), Pancreas Suis, Thymus (suis), Thymus (suis), Alpha-ketoglutaricum Acidum, Cholesterinum, Formicum Acidum, Histaminum Hydrochloricum, Malicum Acidum, Natrum Oxalaceticum, Sulphur, Calcarea Carbonica, |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Dr. Donna Restivo Dc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | .ALPHA.-KETOGLUTARIC ACID - 10 [hp_X]/mL .ALPHA.-LIPOIC ACID - 8 [hp_X]/mL ACETALDEHYDE - 10 [hp_X]/mL AVENA SATIVA FLOWERING TOP - 6 [hp_X]/mL CHELIDONIUM MAJUS - 4 [hp_X]/mL CHOLESTEROL - 10 [hp_X]/mL CINCHONA OFFICINALIS BARK - 8 [hp_X]/mL CYNARA SCOLYMUS LEAF - 6 [hp_X]/mL FORMIC ACID - 10 [hp_X]/mL HISTAMINE DIHYDROCHLORIDE - 10 [hp_X]/mL Load more... LYCOPODIUM CLAVATUM SPORE - 4 [hp_X]/mL MALIC ACID - 10 [hp_X]/mL MENADIONE - 6 [hp_X]/mL METHYLCOBALAMIN - 6 [hp_X]/mL MILK THISTLE - 3 [hp_X]/mL OROTIC ACID MONOHYDRATE - 7 [hp_C]/mL OYSTER SHELL CALCIUM CARBONATE, CRUDE - 28 [hp_X]/mL PORK INTESTINE - 8 [hp_X]/mL PORK LIVER - 8 [hp_X]/mL PROTEUS MORGANII - 30 [hp_C]/mL SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR ENTERITIDIS - 30 [hp_C]/mL SODIUM DIETHYL OXALACETATE - 10 [hp_X]/mL SULFUR - 13 [hp_X]/mL SUS SCROFA COLON - 8 [hp_X]/mL SUS SCROFA DUODENUM - 8 [hp_X]/mL SUS SCROFA GALLBLADDER - 8 [hp_X]/mL SUS SCROFA LYMPH - 8 [hp_X]/mL SUS SCROFA PANCREAS - 8 [hp_X]/mL SUS SCROFA THYMUS - 8 [hp_X]/mL TARAXACUM OFFICINALE - 4 [hp_X]/mL VERATRUM ALBUM ROOT - 8 [hp_X]/mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 25 Nov, 2019 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 09 May, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Dr. Donna Restivo DC |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| UNII: | 8ID597Z82X 73Y7P0K73Y GO1N1ZPR3B MA9CQJ3F7F 7E889U5RNN 97C5T2UQ7J S003A158SB B71UA545DE 0YIW783RG1 3POA0Q644U Load more... C88X29Y479 817L1N4CKP 723JX6CXY5 BR1SN1JS2W U946SH95EE 91532S02AO 2E32821G6I 40GMI0R60L 6EC706HI7F 56X6LID5ZY Y3V16D4PV4 6CA025Y4FG 70FD1KFU70 94J255A0UC P6J2SFT80O B6A98VOI9I 33A7VYU29L 9Y3J3362RY 7B69B0BD62 39981FM375 QNS6W5US1Z |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 62185-0052-1 | 30 mL in 1 BOTTLE, DROPPER (62185-0052-1) | 25 Nov, 2019 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.